Emerging role of precision medicine in biliary tract cancers

James M. Bogenberger, Thomas T. DeLeon, Mansi Arora, Daniel H. Ahn, Mitesh J. Borad

Research output: Contribution to journalReview articlepeer-review

Abstract

Biliary tracts cancers (BTCs) are a diverse group of aggressive malignancies with an overall poor prognosis. Genomic characterization has uncovered many putative clinically actionable aberrations that can also facilitate the prognostication of patients. As such, comprehensive genomic profiling is playing a growing role in the clinical management of BTCs. Currently however, there is only one precision medicine approved by the US Food and Drug Administration (FDA) for the treatment of BTCs. Herein, we highlight the prevalence and prognostic, diagnostic, and predictive significance of recurrent mutations and other genomic aberrations with current clinical implications or emerging relevance to clinical practice. Some ongoing clinical trials, as well as future areas of exploration for precision oncology in BTCs are highlighted.

Original languageEnglish (US)
Article number21
Journalnpj Precision Oncology
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Emerging role of precision medicine in biliary tract cancers'. Together they form a unique fingerprint.

Cite this